Depression trials in Czechia

In Czechia 13 Also abroad 666

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Where
Brno, Plzen 3, Prague, Prague 10
Age
18 years to 65 years
People
360 worldwide
Run by
Seaport Therapeutics
See details and how to joinNCT07065240 · EU 2025-521240-37-00
Phase 2Enrolling by invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
Where
Brno, Plzen 3, Prague, Prague 10
Age
18 years to 66 years
People
360 worldwide
Run by
Seaport Therapeutics
See details and how to joinNCT07161700 · EU 2025-522347-18-00
Phase 3Taking people
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Where
Brno, Plzen 3, Prague, Prague 10
Age
18 years to 74 years
People
752 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06559306 · EU 2023-509070-36-00
Phase 3Taking people
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Where
Plzen 3, Prague
Age
18 years to 85 years
People
330 worldwide
Run by
Cybin IRL Limited
See details and how to joinNCT06793397 · EU 2024-519270-40-00
Phase 3Taking people
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Where
Klecany, Kurim, Plzen 3, Prague, Prague 10
Age
18 years and over
People
850 worldwide
Run by
Neurocrine Biosciences
See details and how to joinNCT06966401 · EU 2024-519423-24-00
Phase 2Taking people
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Where
Ostrava, Prague, Říčany
Age
18 years to 75 years
People
300 worldwide
Run by
Draig Therapeutics Ltd
See details and how to joinNCT07300969
Phase 3Enrolling by invitation
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Where
Plzen 3, Prague
Age
18 years to 85 years
People
468 worldwide
Run by
Cybin IRL Limited
See details and how to joinNCT06605105 · EU 2024-516805-22-00
Phase 3Taking people
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Where
Brno, Plzen 3, Poruba, Prague, Prague 10
Age
18 years to 65 years
People
500 worldwide
Run by
Vanda Pharmaceuticals
See details and how to joinNCT06830044 · EU 2024-520333-68-00
Phase 2Not yet taking people in Czechia
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Where
Kladno, Klecany, Pilsen, Prague
Age
18 years to 65 years
People
200 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07772531
Phase 2Taking people
DT-101 in Adults with Major Depressive Disorder
Where
Poruba, Prague 10, Říčany
Age
18 years and over
People
175 worldwide
Run by
Draig Therapeutics Limited
See details and how to join2025-522784-15-00 · EU 2025-522784-15-00
Phase 2Taking people
Psilocybin Therapy for Psychological Distress in Palliative Patients
Where
Klecany
Age
18 years and over
People
108 worldwide
Run by
University Medical Center Groningen
See details and how to joinNCT06782724 · EU 2023-510488-36-01
No phaseTaking people
Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression
Where
Prague
Age
18 years and over
People
50
Run by
Charles University, Czech Republic
See details and how to joinNCT07324070
Phase 3Taking people
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Where
Plzen 3, Prague, Prague 10
Age
18 years and over
People
200 worldwide
Run by
Neurocrine Biosciences
See details and how to joinNCT06786624 · EU 2024-519418-29-00